61 results about "Macular oedema" patented technology

The present invention discloses β-diketones, γ-diketones or γ-hydroxyketones or analogs thereof, that activate Wnt / β-catenin signaling and thus treat or prevent diseases related to signal transduction, such as osteoporosis and osteoarthropathy; osteogenesis imperfecta, bone defects, bone fractures, periodontal disease, otosclerosis, wound healing, craniofacial defects, oncolytic bone disease, traumatic brain injuries related to the differentiation and development of the central nervous system, comprising Parkinson's disease, strokes, ischemic cerebral disease, epilepsy, Alzheimer's disease, depression, bipolar disorder, schizophrenia; eye diseases such as age related macular degeneration, diabetic macular edema or retinitis pigmentosa and diseases related to differentiation and growth of stem cell, comprising hair loss, hematopoiesis related diseases and tissue regeneration related diseases.

A compound of the formula (I): R<1>-NH-X-Y-Z (I) wherein each symbol is as defined in the specification, or a pharmaceutically acceptable salt thereof useful as a vascular adhesion protein-1 (VAP-1) inhibitor, a pharmaceutical composition, a method for preventing or treating a VAP-1 associated disease, especially macular edema, which method includes administering an effective amount of the compound or a pharmaceutically acceptable salt thereof to a mammal, and the like.

A compound of the formula (I): R1—NH—X—Y-Z (I) wherein each symbol is as defined in the specification, or a pharmaceutically acceptable salt thereof useful as a vascular adhesion protein-1 (VAP-1) inhibitor, a pharmaceutical composition, a method for preventing or treating a VAP-1 associated disease, especially macular edema, which method includes administering an effective amount of the compound or a pharmaceutically acceptable salt thereof to a mammal, and the like.

Embodiments of the invention provide systems and methods for treating the retina and / or other areas of a patient's eye. The procedures may involve using one or more treatment beams (e.g., lasers) to cause photocoagulation or laser coagulation to finely cauterize ocular blood vessels and / or prevent blood vessel growth to induce one or more therapeutic benefits. In other embodiments, a series of short duration light pulses (e.g., between 5-15 microseconds) may be delivered to the retinal tissue with a thermal relaxation time delay between the pulse to limit the temperature rise of the target retinal tissue and thereby limit a thermal effect to only the retinal pigment epithelial layer. Such procedures may be used to treat diabetic retinopathy, macular edema, and / or other conditions of the eye. The treatment beam may be delivered within a treatment boundary or pattern defined on the retina of the patient's eye.

Disclosed herein are compositions comprising one or more antibodies that specifically bind active plasma kallikrein (e.g., human plasma kallikrein) and methods of using such compositions for the treatment of retinal diseases, such as diabetic macular edema.

The invention discloses a composition for treating eye diseases by double-target / multi-target small nucleic acid and applications of the composition. The composition comprises two small nucleic acid molecules and a medicinal carrier, target genes of the two small nucleic acid molecules are selected from two of VEGF (vascular endothelial growth factor) gene, VEGFR2 (vascular endothelial growth factor receptor2) gene and TGF-b1 (transforming growth factor-beta1) gene; or the composition comprises three small nucleic acid molecules and a medicinal carrier, and target genes of the three small nucleic acid molecules are respectively VEGF gene, VEGFR2 gene and TGF-b1 gene. The composition can be used for effectively treating eye diseases by virtue of ribonucleic acid interference (RNAi) mediated inhibitor gene expression and biochemical pathway, and can be prepared to form a medicament for treating eye diseases, including proliferatived diabetic retinophathy, diabetic macular edema, herpes simplex interstitial keratitis, age-related macular degeneration, uveitis and the like.

The present invention relates to fluorinated compounds of formula I and methods of synthesizing these compounds. The present invention also relates to pharmaceutical compositions containing the fluorinated compounds of the invention, and methods of treating macular degeneration, diabetic retinopathy (DR), macular edema, diabetic macular edema (DME), and macular edema following retinal vein occlusion (RVO), by administering these compounds and pharmaceutical compositions to subjects in need thereof.

Provided are methods, pharmaceutical formulations and kits thereof for the treatment and / or prevention of conditions mediated by neovascularization, abnormal angiogenesis, vascular permeability, or combinations thereof, of posterior and / or anterior tissues and fluids of the eye, including conditions associated with proliferative retinopathies, for example, diabetic retinopathy, age-related maculopathy, retinopathy of prematurity, retinopathy associated with macular edema, or retinopathy associated with sickle cell disease, using the topical administration of mecamylamine or a pharmaceutically acceptable salt thereof to the eye. Methods of preparing the pharmaceutical formulations are also provided.

The present invention relates to pharmaceutical formulations comprising an anti angiogenic compound such as a monoclonal antibody or fragment thereof Selected from, for example, ranibizumab, which is a vascular endothelial growth factor binder which inhibits the action of VEGF, and a delivery agent selected from a pharmaceutically acceptable liposome. The formulations are useful in the treatment of a variety of angiogenic disorders and diseases in animals and people, and, preferably, in ophthalmic disorders selected from age-related macular degeneration, diabetic macular edema and corneal neovascularization.

The present invention relates to methods, devices, and compositions for treating ocular disorders such as uveitis, macular edema associated with uveitis, and diabetic macular edema. For example, the methods include treatment of subjects having macular edema associated with non-infectious uveitis, or diabetic macular edema, by administering to the subjects a triamcinolone composition via non-surgical administration to the suprachoroidal space (SCS) of the eye.

The invention discloses a composition for treating fundus macular oedema and application of the composition in treatment of eye diseases and belongs to the technical field of medicines. The composition for treating the fundus macular oedema comprises the following components in percentage by weight: 0.4-71% of (a) polyphenolic compounds, 0.6-93% of (b) lipoic acid, dihydrolipoic acid, lipoic acid salt or lipoamide, 0-97% of (c) ubiquinone or panthenol and 0-87% of (d) docosahexaenoic acid or ethyl ester thereof and / or timnodonic acid or ethyl ester thereof. The composition can be used for improving patient visual acuity, stabilizing intraocular pressure and reducing various ocular inflammations such as the fundus macular oedema. By means of the composition for treating the fundus macular oedema and a treatment method, the fundus macular oedema can be prevented, stabilized, controlled or treated and the fundus health can be enhanced; in the meantime, the intraocular pressure can be stabilized, the vision can be maintained or improved, various eye diseases or macular oedema and inflammation which are caused by eye operations can be reduced; the diabetic complication is also treated, the blood microcirculation is promoted and the liver function is improved.

This invention relates to CXCR4 inhibitors and their use in treating and / or preventing a variety of angiogenic, microvascular and ocular disorders including primary indications for diabetic retinopathy, macular degeneration (such as wet or neovascular age-related macular degeneration (AMD) and dry or atrophic AMD), macular edema, and secondary indications for inhibiting tumor vascularization, and corneal and iris neovascularization.

Eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), or a salt or an ester thereof, are provided for use in the treatment and / or prophylaxis of a condition selected from macular oedema, conditions causing damage to retinal photoreceptors and / or retinal pigment epithelial cells, and dry eyes in a mammal, wherein the combined dosage of eicosapentaenoic acid and docosahexaenoic acid is from 5 mmol to 25 mmol per day, and wherein the molar ratio of eicosapentaenoic acid to docosahexaenoic acid is in the range of from 1:1 to 5:1. Compositions comprising EPA and DHA and at least one pharmaceutically acceptable excipient, and kits containing EPA, DHA and further therapeutic agents are also provided. The EPA and DHA, or composition comprising the EPA and DHA may be administered orally.

The invention provides an automatic screening method for diabetic macular edema based on transfer learning, which comprises the following steps: marking whether diabetic macular edema exists through an optical coherence tomography image and fundus color photograph; extracting eye features of a patient by using the trained deep residual neural artificial intelligence model, classifying whether diabetic macular edema exists according to the eye features, and performing polarity adjustment on the deep residual neural artificial intelligence model by using fundus color photograph data set trainingthrough a transfer learning technology; and obtaining a final intelligent screening model of diabetic macular edema based on fundus color photograph. The optical coherence tomography image and the fundus color photograph are used for identifying and classifying patients suffering from diabetic macular edema or not through the fundus color photograph-based intelligent screening model for diabeticmacular edema, so that the screening accuracy and the working efficiency of diabetic macular edema high-risk groups can be improved, and the expenditure of disease diagnosis and treatment of the patients is also reduced; therefore, more patients can be diagnosed and treated in time.

The invention provides application of total flavones of hippophae rhamnoides in preparation of treating diabetic retinopathy. The invention also provides a medicine composition for treating the diabetic retinopathy. The medicinal flavonoid compound can be used for resisting the oxidative damage of hydrogen peroxide, improving the activity of cells as well as the oxidation reduction function, and bringing protection to the retinal pigment epithelium (RPE), so that photoreceptor cells can be protected, the macular oedema is reduced, the vision is improved, and the total flavones of hippophae rhamnoides are expected to be developed into a new medicine for treating the diabetic retinopathy.

This invention relates to the use of a heparanase inhibitor for treating, or inhibiting the progression or development of, an ocular inflammatory disorder, such as age-related macular degeneration, diabetic retinopathy, retinitis pigmentosa, retinal 5 vein occlusion, retinoblastoma, uveitis, macular edema, dry eye, ocular inflammation associated with an infection or keratoconus.

The invention belongs to the field of the medical technology, and particularly relates to traditional Chinese medicine for treating diabetes mild macular oedema. The traditional Chinese medicine includes the following traditional Chinese medicine bulk drugs of, by weight, 8-16 parts of American ginseng, 8-16 parts of atractylodes macrocephala koidz, 8-16 parts of astragalus membranaceus, 11-19 parts of poria cocos, 11-19 parts of cortex periplocae, 8-16 parts of rhizoma atractylodis, 8-16 parts of mangnolia officinalis, 8-16 parts of leonurus, 8-16 parts of cowherb seeds, 2-4 parts of semen lepidii, 5-13 parts of exocarpium, 5-13 parts of platycodon grandiflorum, 5-13 parts of prunella vulgaris and 8-16 parts of eriocaulon cinereum. By the adoption of the traditional Chinese medicine, absorption of the macular oedema can be prompted, restoration of the retina form is assisted, eyesight is effectively improved, and the visual function is improved.

The present invention relates to compounds of general formula (i) having an oxime moiety or a pharmaceutically acceptable salt, hydrate or solvate thereof and its use for inhibiting semicarbazide-sensitive amine oxidase (SSAO), also known as vascular adhesion protein-1 (VAP-1), a pharmaceutical composition comprising the compound or a salt, hydrate or solvate thereof as an active ingredient, a method for the prevention or the treatment of a SSAO / VAP-1 related disease, said diseases including acute or chronic inflammatory diseases, diseases related to carbohydrate metabolism, diabetes-associated complications, diabetic retinopathy and macular oedema, diseases related to adipocyte or smooth muscle dysfunctions, neurodegenerative diseases and vascular diseases.

The invention discloses an eyesight-improving decoction for treating diabetic retinopathy, which is prepared from the traditional Chinese raw material medicines comprising, by weight, 10-30 parts of astragalus membranaceus, 10-20 parts of codonopsis pilosula, 10-20 parts of poria cocos, 10-30 parts of salviae miltiorrhizae, 10-20 parts of kudzu roots, 5-15 parts of rhizoma anemarrhenae, 10-20 parts of angelica sinensis, 10-20 parts of white peony roots, 10-20 parts of rhizoma alismatis, 10-30 parts of semen plantaginis, 10-20 parts of rhizoma imperatae, 5-15 parts of cacumen biotae, 5-10 parts of honey-fried liquorice, 10-20 parts of radix rehmanniae preparata, 10-20 parts of fructus lycii, 10-20 parts of chinese yam, 10-20 parts of chrysanthemum, 5-15 parts of butterflybush flower, 5-15 parts of fructus leonuri and 10-20 parts of herba lycopi. The raw material medicines are combined to achieve the effects of boosting qi and activating blood, promoting urination and tonifying kidney, and improving eyesight. The decoction can reduce retinal hemorrhage and exudation, can promote absorption thereof and can promote absorption of macular oedema after retinal photocoagulation operation.

[Problem] To provide an anti-human Tie2 antibody which prevents or treats diabetic macular edema, diabetic retinopathy, or critical limb ischaemia by binding to human Tie2 and activating human Tie2. [Solution] The inventors of the present invention studied anti-human Tie2 antibodies and have provided an anti-human Tie2 antibody including four heavy chain variable regions and four light chain variable regions. The heavy chain variable regions comprise an amino acid sequence from amino acid no. 1 to 122 of SEQ ID NO:2, and the light chain variable regions comprise an amino acid sequence from amino acid No. 1 to 113 of SEQ ID NO:4. One of the heavy chain variable regions and one of the light chain variable regions constitute one antigen-binding site, and the antibody includes four antigen-binding sites.

The present invention relates to compounds of general formula (i) having an oxime moiety or a pharmaceutically acceptable salt, hydrate or solvate thereof and its use for inhibiting semicarbazide-sensitive amine oxidase (SSAO), also known as vascular adhesion protein-1 (VAP-1), a pharmaceutical composition comprising the compound or a salt, hydrate or solvate thereof as an active ingredient, a method for the prevention or the treatment of a SSAO / VAP-1 related disease, said diseases including acute or chronic inflammatory diseases, diseases related to carbohydrate metabolism, diabetes-associated complications, diabetic retinopathy and macular oedema, diseases related to adipocyte or smooth muscle dysfunctions, neurodegenerative diseases and vascular diseases.

The present disclosure relates to a novel use of a sesquiterpene derivative, more particularly to a composition for preventing, improving or treating macular degeneration or macular edema caused by vascular leakage in the eye, the composition containing a sesquiterpene derivative compound represented by Chemical Formula 1 of the present disclosure or a pharmaceutically acceptable salt thereof as an active ingredient. Whereas the intraocular disease-related treating agents available in the market should be injected directly into the vitreous cavity, thus causing pain and side effects, the sesquiterpene derivative compound of the present disclosure is delivered to the target tissue (eye) via different administration routes (oral, intraperitoneal, etc.) other than the intravitreal route. Accordingly, the sesquiterpene derivative compound provides excellent therapeutic effect without being restricted by the administration routes.

The invention provides application of total flavones of hippophae rhamnoides in preparation of treating diabetic retinopathy. The invention also provides a medicine composition for treating the diabetic retinopathy. The medicinal flavonoid compound can be used for resisting the oxidative damage of hydrogen peroxide, improving the activity of cells as well as the oxidation reduction function, and bringing protection to the retinal pigment epithelium (RPE), so that photoreceptor cells can be protected, the macular oedema is reduced, the vision is improved, and the total flavones of hippophae rhamnoides are expected to be developed into a new medicine for treating the diabetic retinopathy.

The invention provides an ophthalmic preparation for treating macular edema, optic neuritis and non-infectious entophthalmia. The ophthalmic preparation is composed of an active ingredient for treating eye diseases and an ophthalmic preparation carrier or auxiliary material; the active ingredientfor treating the eye diseases is a glucocorticoid medicine and / or a non-steroidal medicine; the ophthalmic preparation carrier or auxiliary material comprises the following ingredients: a surfactant, an ionic polymer and a solvent, or the ophthalmic preparation carrier or auxiliary material contains the following ingredients: povidone with low polymerization degree, povidone with medium polymerization degree and a solvent. The ophthalmic preparation can carry (wrap) the glucocorticoid and / or the non-steroidal medicines to penetrate through the anterior segment of the eye and be conveyed to the posterior segment of the eye to treat the macular edema, the optic neuritis and the non-infectious entophthalmiain an eye drop administration mode, and the ophthalmic preparation has extremely excellent clinical use value and very positive social significance.

The invention provides application of a composition prepared from radix astragali, radix puerariae and herba erigerontis to preparation of drugs for treating or preventing macular oedema of individuals.

The present invention is directed to multi-tyrosine kinase inhibitor compounds. The present invention is further directed to compositions comprising those compounds. Finally, the present invention is directed to methods of treating eye conditions including, but not limited to, diabetic background retinopathy, diabetic macular edema, diabetic proliferative retinopathy, diabetic macular edema with proliferative retinopathy, proliferative fibrovascular disease, diabetic macular edema with proliferative fibrovascular disease, retinopathy of prematurity, dry macular degeneration, dry macular degeneration with drusen and wet macular degeneration, using compounds and compositions of the invention.

The invention provides buffered aqueous formulations of bevacizumab. The invention further provides methods of making buffered formulations of bevacizumab. The invention provides methods of treating eye disorders, particularly wet age-related macular degeneration and macular edema by administering the buffered antibody compositions of the disclosure.

The present invention relates to fusion molecules and chimeric molecules comprising two components: Ang2 antagonist peptides linked to VEGF binding moieties. Further disclosed are methods of treatingcancer, proliferative retinopathy, neovascular glaucoma, macular edema, wet age-related macular degeneration (wAMD), macular edema after retinal vein occlusion (RVO), diabetic macular edema (DME), ordiabetic retinopathy (DR) in a patient using the chimeric molecules.

Provided are methods, pharmaceutical formulations and kits thereof for the treatment and / or prevention of conditions mediated by neovascularization, abnormal angiogenesis, vascular permeability, or combinations thereof, of posterior and / or anterior tissues and fluids of the eye, including conditions associated with proliferative retinopathies, for example, diabetic retinopathy, age-related maculopathy, retinopathy of prematurity, retinopathy associated with macular edema, or retinopathy associated with sickle cell disease, using the topical administration of mecamylamine or a pharmaceutically acceptable salt thereof to the eye. Methods of preparing the pharmaceutical formulations are also provided.